Navigation Links
Forty-two of Simcere's Generic Drugs Enter China's Essential Drug List
Date:8/21/2009

NANJING, China, Aug. 21 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that forty-two of its generic drugs have been included in China's Essential Drug List ("EDL"), which was issued by China's Ministry of Health ("MOH") on August 18, 2009.

In the 2009 second quarter earnings conference call, the Company announced that seven of its generics entered China's EDL. These seven medicines are branded generics, which are currently manufactured with significant sales or large market potential. The other generics comprising the forty-two medicines are seldom manufactured or have had insignificant sales in recent years.

The EDL issued by the MOH consists of 307 essential medicines that will be given priority for basic healthcare. All of these medicines will be included in the National Medical Insurance Catalog. The insurance reimbursement rate of these medicines will be higher than other medicines. Simcere is one of China's pharmaceutical companies with the largest number of generics in China's EDL.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "We are delighted to have forty-two of Simcere's generics included in China's Essential Drug List. While maintaining our focus on first-to-market and innovative drugs, we will evaluate market opportunities to update our strategy in generics sales to leverage the opportunities presented by the Essential Drugs List. We are confident that Simcere will benefit from China's ongoing healthcare reform over the mid-to-long term."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
2. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
3. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
4. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
5. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
6. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
7. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
10. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
11. Hospira Supports Newly Introduced Biogenerics Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... FRANCISCO , February 12, 2016 ... Medicine Efforts by Enabling Scientific Understanding of Complex ... and Rare Diseases --> ... genomic diagnostics in South Asia and a leading provider ... would contribute $10 million to the GenomeAsia 100K ...
(Date:2/11/2016)...  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its ... --> --> For the ... $29.3 million, or $0.34 loss per share, compared to a net ... same period in 2014. For the year ended December 31, 2015, ... loss per share, as compared to a net loss of $60.5 ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , February 11, ... Standard: QIA) today announced the introduction of more than ... profiling, expanding QIAGEN,s portfolio of Sample to Insight solutions ... select from over 20,000 human genes and lncRNA to ... cellular phenotypes and disease processes. --> QGEN ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
Breaking Biology Technology:
(Date:1/21/2016)... 2016 --> ... research report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, ... Expression, Voice Recognition and Others), Services, Application Areas, ... 2020", published by MarketsandMarkets, the global Emotion Detection ... 22.65 Billion by 2020, at a CAGR of ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):